While the insurers approximately $3 billion in reserves can help absorb such losses, three consecutive years of such huge numbers amount to a meaningful hit
Unlike semaglutide which activates only GLP-1 receptors, or tirzepatide which targets GLP-1 and GIP, retatrutide simultaneously activates three hormone receptors
Many companies are concerned about the high upfront-costs only to have people discontinue the drugs, negating the long-term benefits, said Ben Barner, clinical pharmacy leader at insurance brokerage Brown & Brown
In contrast, oral semaglutide, even at higher doses, typically offers a bit less, with some studies reporting an average weight loss of 13.6% (source)
Risks of Switching from GLP-1 Injections to Patches Switching from clinically approved injections to unverified patches can lead to several setbacks: Loss of progress : Users may regain weight and need to restart injections from scratch
Adrenaline (via activation of -adrenoceptors, elevation of cAMP and mobilisation of intracellular [Ca 2+ ] i ) is a powerful glucagon secretagogue [22]
